CompletedPhase 4

A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine

United States100 participantsStarted 2025-10-20

Plain-language summary

This prospective, single-arm feasibility study will evaluate postoperative pain control, opioid use, and early recovery outcomes in adult patients undergoing elective outpatient facial plastic surgery who receive suzetrigine as part of their standard postoperative analgesic regimen.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults (≥18 years) undergoing elective outpatient facial plastic surgery. * Able to consent and comply with study procedures. * Planned postoperative use of suzetrigine per provider discretion. Exclusion Criteria: * Age \<18. * Pregnant or breastfeeding. * Women on hormonal birth control who decline suzetrigine-related counseling. * Patients using strong CYP3A4 inhibitor medications (i.e. itraconazole, ketoconazole, clarithromycin, ritonavir, and grapefruit juice). * Known allergy to suzetrigine. * Vulnerable or protected research populations.

What they're measuring

Total opioid consumption

Timeframe: 7 days post-operation

Number of patients with no rescue use

Timeframe: 7 days post-operation

Trial details

NCT IDNCT07257133

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03-01

View on ClinicalTrials.gov More Post Operative Pain trials